Heterologous expression of lacticin 3147 in Enterococcus faecalis: comparison of biological activity with cytolysin.

The study investigates the biological activity of a bacteriocin, lacticin 3147, in comparison to another bacteriocin, cytolysin. The research demonstrates that lacticin 3147 can be expressed in a different bacterial species, Enterococcus faecalis, and can maintain its antimicrobial activity without exhibiting harmful effects on blood cells.

Objective of the Study

• The main objective of the research was to compare the biological activity of two bacteriocins, lacticin 3147 and cytolysin.

Background of the Study

• The paper begins by explaining that lacticin 3147 is a bacteriocin – a type of antimicrobial compound produced by bacteria – and has a wide range of potential applications in food and medicine.
• It discusses another bacteriocin called cytolysin, produced by Enterococcus faecalis, which has an associated haemolytic activity, meaning it can break down red blood cells.

Methodology

• The researchers carried out their comparison by introducing the genetic material responsible for the production of lacticin 3147 into Enterococcus faecalis.
• This allowed them to directly compare the effects of lacticin 3147 and cytolysin when produced by the same species of bacteria.

Findings

• The study concluded that lacticin 3147 retains its broad antimicrobial activity when expressed in Enterococcus faecalis.
• Unlike cytolysin, lacticin 3147 expressed in Enterococcus faecalis did not show any haemolytic activity, indicating that it did not harm blood cells.

Implications

• The results of this study could have significant implications for the use of bacteriocins in the food industry and biomedicine.
• If lacticin 3147 can be expressed in a different species like Enterococcus faecalis, while retaining its antibacterial properties and avoiding harmful effects on blood cells, it could prove a useful tool in the fight against bacterial infections.